Table 4.
Efficacy
| Cohort | No. of Patients | Objective Response |
Response Duration (weeks) | Stable Disease ≥ 24 Weeks |
Progression-Free Survival Rate at 24 Weeks (%) | |||
|---|---|---|---|---|---|---|---|---|
| No. | % | 95% CI (%) | No. | % | ||||
| Ipilimumab-naive patients | ||||||||
| Cohort 1 | 10 | 3 | 30 | 6.7 to 65.3 | 140+, 128+, 76+ | 2 | 20 | 50 |
| Cohort 2 | 13 | 4 | 31 | 9.1 to 61.4 | 84+, 36, 24, 24 | 1 | 8 | 39 |
| Cohort 3 | 11 | 1 | 9 | 0.2 to 41.3 | 84+ | 4 | 36 | 45 |
| Patients who received prior ipilimumab | ||||||||
| Cohort 4 | 10 | 3 | 30 | 6.7 to 65.3 | 60+, 60+, 60+ | 2 | 20 | 50 |
| Cohort 5 | 5 | 1 | 20 | 0.5 to 71.6 | 36+ | 2 | 40 | 60 |
| Cohort 6 | 38 | 10 | 26 | 13.4 to 43.1 | 48+, 36+, 36+, 36+ | 7 | 18 | 44 |
| All cohorts | 87 | 22 | 25 | 16.6 to 35.8 | 36+, 24+, 24+, 24+ 24+, 12+ | 18 | 21 | 46 |